Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers January 22, 2019
Pharmacy Choice - Pharmaceutical News - Amgen and UCB`s Evenity approved in Japan for osteoporosis [Syrian Arab News Agency] - January 22, 2019

Pharmacy News Article

 1/11/19 - Amgen and UCB`s Evenity approved in Japan for osteoporosis [Syrian Arab News Agency]

Amgen has revealed that its bone-forming monoclonal antibody Evenity (romosozumab), developed in partnership with UCB Pharma, has been awarded approval in Japan for the treatment of osteoporosis in patients at high risk of fracture.

The decision, which precedes final verdicts in the US and Europe, where review is currently ongoing, was based on Phase 3 data from two studies encompassing 7,180 postmenopausal women and 245 men with osteoporosis, finding the drug to be both safe and effective following a robust review.

Under the established partnership, the Tokyo-headquartered joint venture between Amgen and Astellas known as Amgen Astellas BioPharma KK (AABP) led development of the drug in the country. The drug works by increasing bone formation and decreasing bone resorption, bolstering bone mineral density (BMD) and minimising the risk of fracture.

"The approval of Evenity in Japan is a significant milestone that reinforces our commitment to bringing effective treatments to the millions of patients who suffer from osteoporosis," said David M Reese, Amgens Executive Vice President of Research and Development. "A patient with a prior osteoporotic fracture is twice as likely to suffer another fracture if left undiagnosed and without appropriate treatment. With this approval, physicians in Japan now have a new medicine to help patients reduce their risk of fracture."

Steve Sugino, Amgens Vice President and President and Representative Director of AABP, also remarked: "In Japan, osteoporotic fracture is one of the leading causes for patients losing independence and needing nursing care. As the aged population of Japan increases, preventing such fractures should be given high priority. Japanese patients will be the first in the world to have a new therapeutic option for osteoporosis that reduces the risk of fracture by not only increasing bone formation but also decreasing bone resorption."

Age is one of the foremost risk factors in developing osteoporosis, and with over 37% of the Japanese population forecast to be 60 years old or older by 2050, the approval could prove a crucial one in the coming years. The condition already affects around 12 million in the country today.



(c) International 2006-2019, SANA Provided by SyndiGate Media Inc. (Syndigate.info).

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

LIVE ONLINE CE

Last Chance
Jan 22: Medication Use During Pregnancy & Lactation
Last Chance
Jan 23: ADHD in Children & Adults: Etiology, Pathology, Pharmacotherapy
Jan 24: COPD Update for Pharmacy Professionals
Jan 28: From Memory to Alzheimer’s - Supporting Memory With Lifestyle Medicine
Jan 29: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.



Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415